Bianchi R, Pilo A, Mariani G, Molea N, Cazzuola F, Ferdeghini M, Bertelli P
J Clin Endocrinol Metab. 1984 Jun;58(6):993-1002. doi: 10.1210/jcem-58-6-993.
A further development of a new method recently proposed for the direct measurement of the conversion ratio (CR) of T4 to T3 in man is presented. [125I]T4 and [131I]T3 are injected simultaneously, and Sephadex chromatography is performed on urine samples to determine [125I]T3 formed in vivo, while plasma samples are used to measure the injected tracers. CR is calculated with the assumption that urinary [125I]T3 closely reflects [125I]T3 appearing in plasma after the injection of precursor [125I]T4. Four normal subjects and six patients with various thyroid disorders were studied using this method. The experimental data were also analyzed by our previous method based on plasma sampling only and by two recently described methods based on urinary measurements. These comparisons were made in an attempt to ascertain whether there is any systematic difference between the conversion values derived from plasma data and those derived from urinary data. Using plasma data alone, the CR was 28.6 +/- 3.4% (mean +/- SEM) in a group of four normal subjects, 37%, in two untreated hypothyroid patients, 40.2% in one hypothyroid subject receiving T4 treatment, 30.9% in one hyperthyroid patient, 24.9% in one patient with selective hyperthyroxinemia due to amiodarone treatment, and 10.7% in one normal subject after iopanoic acid administration. These values were in excellent agreement with those obtained by the modified procedure described here, in which both urinary and plasma measurements are used. Of the methods using urinary data alone, however, one gave similar results, while the other systematically overestimated the CR, possibly due to delayed excretion of labeled T4 metabolites into the urine. We conclude that 1) the analytical procedure to separate the labeled tracers and metabolites in urine or plasma is critical for the accurate estimation of CR; 2) when an adequate separation procedure is available, plasma and urinary methods for measuring CR yield comparable results; and 3) the plasma method should be used when, in addition to CR, other kinetic (distribution and turnover) parameters of T4 and T3 metabolism are to be estimated.
本文介绍了最近提出的一种直接测量人体中T4向T3转化率(CR)的新方法的进一步发展。同时注射[125I]T4和[131I]T3,对尿液样本进行葡聚糖凝胶色谱分析以测定体内形成的[125I]T3,而血浆样本用于测量注入的示踪剂。计算CR时假设尿中[125I]T3能密切反映注射前体[125I]T4后血浆中出现的[125I]T3。使用该方法对4名正常受试者和6名患有各种甲状腺疾病的患者进行了研究。实验数据还通过我们之前仅基于血浆采样的方法以及最近描述的两种基于尿液测量的方法进行了分析。进行这些比较是为了确定从血浆数据得出的转化率值与从尿液数据得出的转化率值之间是否存在任何系统差异。仅使用血浆数据时,一组4名正常受试者的CR为28.6±3.4%(平均值±标准误),2名未经治疗的甲状腺功能减退患者为37%,1名接受T4治疗的甲状腺功能减退受试者为40.2%,1名甲状腺功能亢进患者为30.9%,1名因胺碘酮治疗导致选择性高甲状腺素血症的患者为24.9%,1名服用碘番酸后的正常受试者为10.7%。这些值与这里描述的改进方法所获得的值非常一致,该改进方法同时使用了尿液和血浆测量。然而,在仅使用尿液数据的方法中,一种方法给出了相似的结果,而另一种方法则系统地高估了CR,这可能是由于标记的T4代谢产物向尿液中的排泄延迟所致。我们得出以下结论:1)在尿液或血浆中分离标记示踪剂和代谢产物的分析程序对于准确估计CR至关重要;2)当有适当的分离程序时,测量CR的血浆和尿液方法产生可比的结果;3)当除了CR之外还需要估计T4和T3代谢的其他动力学(分布和周转)参数时,应使用血浆方法。